Drug giant Pfizer Inc. said Tuesday that it plans to pare an unspecified number of jobs at its Cambridge research center, opened last June, as part a broader cutback across its research operations.
“Pfizer’s research and development organization periodically makes adjustments to its staffing mix to respond to shifting priorities in the [drug] portfolio and the need for the right pool of talent to deliver on these priorities,” the company said in a statement.
The statement said Pfizer would make “select headcount reductions in certain areas of R&D,” which it didn’t identify, while shifting some employees to, and hiring new ones, in growing areas, such as gene therapy and cancer. Pfizer recently struck a cancer immunotherapy alliance with Rockland-based EMD Serono, a US division of Germany’s Merck Serono.
Pfizer last summer consolidated several Boston area sites into its new research center outside Kendall Square, which employed about 1,000 researchers and scientists. The company wouldn’t say how many of those employees will be affected by the cuts.
“As the R&D ecosystem evolves, Pfizer will continue to ensure that we have the right talent and capabilities focused in the right areas so that we can execute on our strategy of advancing Pfizer’s next wave of innovation for the benefit of patients in need,” the company’s statement said.